Abstract

Hepatitis B virus (HBV) chronically infects more than 240 million people worldwide, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Genome editing using CRISPR/Cas9 could provide new therapies because it can directly disrupt HBV genomes. However, because HBV genome sequences are highly diverse, the identical target sequence of guide RNA (gRNA), 20 nucleotides in length, is not necessarily present intact in the target HBV DNA in heterogeneous patients. Consequently, possible genome-editing drugs would be effective only for limited numbers of patients. Here, we show that an adenovirus vector (AdV) bearing eight multiplex gRNA expression units could be constructed in one step and amplified to a level sufficient for in vivo study with lack of deletion. Using this AdV, HBV X gene integrated in HepG2 cell chromosome derived from a heterogeneous patient was cleaved at multiple sites and disrupted. Indeed, four targets out of eight could not be cleaved due to sequence mismatches, but the remaining four targets were cleaved, producing irreversible deletions. Accordingly, the diverse X gene was disrupted at more than 90% efficiency. AdV containing eight multiplex gRNA units not only offers multiple knockouts of genes, but could also solve the problems of heterogeneous targets and escape mutants in genome-editing therapy.

Highlights

  • Hepatitis B virus (HBV) causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC)

  • We showed that eight multiplex guide RNA (gRNA) expression units were stably maintained in the adenovirus vector (AdV) genome

  • Using this AdV, we showed that the HBV X DNA present in a cellular chromosome derived from a heterogeneous patient could be simultaneously cleaved at four or five expected sites, producing irreversible deletions

Read more

Summary

Introduction

Hepatitis B virus (HBV) causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Current anti-HBV treatments with either nucleoside/nucleotide analogs or interferon-α cannot eliminate the virus, and relapse is common [2]. There is an urgent need to cure chronic HBV patients in a fundamentally different way. Chronic HBV infection is a major risk factor for the development of HCC, accounting for 60% of cases worldwide [3]. Integrated viral DNA has been reported in approximately 85% of HBV-related HCC cases [4,5,6]. The HBV X gene is often integrated into a chromosome in HCC cases [7] and correlated with HCC development and progression [8,9,10,11]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.